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To address the problem of specificity in G-protein
coupled receptor (GPCR) drug discovery, there has
been tremendous recent interest in allosteric
drugs that bind at sites topographically distinct
from the orthosteric site. Unfortunately, struc-
ture-based drug design of allosteric GPCR ligands
has been frustrated by the paucity of structural
data for allosteric binding sites, making a strong
case for predictive computational methods. In this
work, we map the surfaces of the b1 (b1AR) and b2
(b2AR) adrenergic receptor structures to detect a
series of five potentially druggable allosteric sites.
We employ the FTMAP algorithm to identify ’hot
spots’ with affinity for a variety of organic probe
molecules corresponding to drug fragments. Our
work is distinguished by an ensemble-based
approach, whereby we map diverse receptor con-
formations taken from molecular dynamics (MD)
simulations totaling approximately 0.5 ls. Our
results reveal distinct pockets formed at both sol-
vent-exposed and lipid-exposed cavities, which we
interpret in light of experimental data and which
may constitute novel targets for GPCR drug dis-
covery. This mapping data can now serve to drive
a combination of fragment-based and virtual
screening approaches for the discovery of small
molecules that bind at these sites and which may
offer highly selective therapies.
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G-protein coupled receptors (GPCRs) represent a large and diverse
superfamily of integral membrane proteins, triggering a wide range of
signal transduction pathways in response to such stimuli as neuro-
transmitters, hormones and photons (1,2). Their ubiquity in the human
genome and engagement in key physiological processes makes them
a top class of pharmaceutical target (3). Testament to this, GPCRs are
associated with approximately 30% of current drugs (4) and are linked
to such diseases as cancer (5) and those of the cardiovascular and
central nervous systems (6,7).
Despite encompassing over 1000 members, spread over six subfami-
lies (8), GPCRs share a common architecture consisting of seven
transmembrane a-helices (TM1–TM7) connected by three intracellu-
lar loops (ICL1-ICL3) and three extracellular loops (ECL1-ECL3).
Recent experimental evidence has demonstrated that GPCRs are
highly dynamic structures, embracing a spectrum of conformational
states from fully inactive through fully active (9). GPCR activity is
manifested through their stimulation of G-proteins, which interact
with the intracellular face of GPCRs and, in turn, engage with
effector proteins to regulate levels of second-messenger molecules
(10). Most GPCRs appear to possess an intrinsic, basal level of
activity in the absence of any ligand. The binding of ligands (from
the extracellular medium) then shifts the conformational equilibrium
toward the fully active state in the case of agonists and toward
the fully inactive state in the case of inverse agonists (11). To fur-
ther emphasize the conformational heterogeneity of GPCRs, it has
been established that ligands can regulate different downstream
signalling cascades through the same GPCR. This phenomenon is
known as 'functional selectivity' and is thought to reflect the ability
of different ligands to stabilize highly specific receptor conforma-
tions (12).
G-protein coupled receptor structural biology has recently enjoyed a
boom (13), with high-resolution crystallographic structures now
available for the avian b1 adrenergic receptor (b1AR) (14), human
b2 adrenergic receptor (b2AR) (15–17) and human adenosine A2A
receptor (18), as well as the proposed active conformation of bovine
opsin in complex with a G-protein fragment (19). These structures
have yielded great insights into the structure–function relationship
between ligand binding and G-protein activation, whereby ligands
are thought to stabilize ⁄ induce a variety of conformational rear-
rangements, which are characteristic of different states and can
have diverse downstream effects (20–22). From a drug design per-
spective, the structures have afforded a detailed picture of the
ligand-binding pocket, formed in an extracellular cleft leading to the
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transmembrane core, and have opened new drug discovery avenues
(23). For example, new structure-based virtual screening efforts
have emerged, in a traditionally ligand-based field, reporting the
successful discovery of several new active compounds (24,25).
References to the GPCR ligand-binding site have, hitherto, alluded
to the 'orthosteric' site, which is defined as the pocket bound by
the endogenous activating ligand (26). GPCR drug discovery to date
has predominantly been concerned with this site, yielding an
impressive repertoire of drugs that compete with the endogenous
ligand and generate a variety of efficacies. Such orthosteric ligands
include well-known examples such as the anti-hypertension drug
atenolol and the anti-asthma drug salbutamol. However, there has
been formidable recent interest in compounds that modulate GPCR
activity through an 'allosteric' mechanism [as reviewed in (26–29)].
Such allosteric ligands bind to a site that is topographically distin-
guished from the orthosteric site (OS) and thus do not compete
with orthosteric ligands (30). Allosteric ligands may (i) modify the
binding and ⁄ or efficacy properties of an orthosteric ligand (termed
'allosteric modulators') or (ii) affect the activation state of the GPCR
by themselves (termed 'allosteric agonists') (31). The binding of an
allosteric ligand may therefore be considered to stabilize ⁄ induce
GPCR conformations that either increase ⁄ decrease the affinity of
orthosteric ligand binding and ⁄ or affect G-protein stimulation. The
main allure of allosteric ligands is their potential for greater recep-
tor selectivity, by binding to specific GPCR subtypes (26). The strong
evolutionary conservation of the OS (across closely related GPCRs)
has caused problems with cross-reactivity of orthosteric ligands,
which can lead to undesirable therapeutic side-effects. For example,
orthosteric drugs that act on the b1AR for the treatment of heart
disease may cross-react with the b2AR and cause unwanted pulmo-
nary effects (and vice-versa for anti-asthma drugs that can cause
cardiac effects) (32). Similarly, the development of orthosteric anti-
psychotic drugs, acting at the muscarinic acetylcholine receptor, has
been plagued with a lack of subtype specificity, leading to side-
effects and motivating the discovery of more selective allosteric
drugs (33). The amino acid sequences of allosteric binding sites are
more likely to have diverged among members of a receptor subclass
than the OS, therefore conferring specificity and reducing the
potential for off-target activity. A key advantage of allosteric modu-
lators is that they exert no effect by themselves, serving only to
tune the effect of endogenous ligands and thus causing less disrup-
tion to the normal physiological profile of the GPCR. This activity
also has implications for toxicity, whereby, because the effect of
allosteric modulators is saturable, overdose-associated risks are
reduced. Finally, it has been noted that allosteric ligands identified
to date display greater structural diversity than their orthosteric
counterparts, thus opening up their chemical space and making
them more amenable to modifications to solve ADMET problems
(34). In summary, allosteric GPCR ligands have generated consider-
able excitement in the field of GPCR drug discovery and offer vari-
ous modes of receptor modulation, with a degree of specificity
unattainable at the OS.
Allosteric GPCR ligands have now been described for a wide range of
GPCRs, including members from all three human classes (26,27,29).
Two allosteric drugs have already been FDA-approved: cinacalcet,
which binds the calcium-sensing receptor in hyperparathyroidism, and
maraviroc, which binds the CCR5 chemokine receptor in HIV infection,
as well as several candidates undergoing clinical studies (35).
Perhaps the two best studied subclasses are those of the muscarinic
receptors (Class A) and the metabotropic glutamate receptors
(Class C), which bind allosteric ligands with diverse pharmacological
activities and play important roles in the diseases of the central
nervous system (6). Despite encouraging progress in the discovery
and functional characterization of allosteric GPCR ligands, the
structural biology of their binding sites is still poorly understood.
An outstanding question is where do they bind? Site-directed muta-
genesis has been employed to give the approximate locations and
identify interacting residues for several allosteric ligands and recep-
tors (31). Such experimental mapping studies have been invaluable
in providing the first details of interaction sites and exposing their
diversity, occurring in both solvent-exposed and bilayer locations (6).
However, given the time and labor-intensive nature of such methods,
as well as the need for an existing allosteric ligand, there is a strong
case for the implementation of faster, more predictive approaches
with which to identify putative allosteric binding sites. Such tools
are particularly germane in the case of GPCRs, which have proven
especially difficult to crystallize and therefore do not enjoy the same
degree of structural data which has supported allosteric drug design
in soluble proteins, such as kinases (34). Establishing the topographi-
cal location of allosteric sites in GPCRs would drive the structure-
based, de novo discovery of allosteric ligands and help elucidate the
structural basis of their function.
The recent milestone of high-resolution structural data for ligand-
activated GPCRs provides a role for computational methods in allo-
steric drug discovery. The motivation to uncover new drug binding
sites is not a new one and has been fueled by the characterization
of several recent sites which have therapeutic potential (36). Given
the three-dimensional structure of a target protein, a number of
algorithms have been developed to scan the entire protein surface
for cavities, which are capable of binding small molecules and are
potentially druggable [as reviewed in (37,38)]. Such methods aim to
detect and score such pockets based on various concepts of molec-
ular recognition. These range from a purely geometric treatment of
the binding pocket [e.g. PocketPicker (39)] to more rigorous energy-
based calculations that typically attempt to dock a series of probe
molecules to candidate pockets and estimate the strength of their
interaction [e.g. GRID (40)]. FTMAP (41) is one of the most recent
energy-based mapping algorithms and was originally conceived as a
faster, computational equivalent of an experimental technique
known as the multiple solvent crystal structures (MSCS) method
(42). With the MSCS approach, the target protein is co-crystallized
in the presence of diverse organic solvent probe molecules, and it
has been demonstrated that the probes tend to cluster at function-
ally important sites. Similarly, FTMAP docks a panel of 16 probe
molecules (representing a variety of functional groups and drug
fragments) to the protein surface and uses an empirical scoring
function to determine low-energy poses. FTMAP is distinguished
from other methods by a combination of its clustering scheme,
which differentiates between consensus sites (CSs) (which repre-
sent putative binding sites) and isolated, non-specific binding
events and an efficient sampling method (41). FTMAP (and its
predecessor CS-Map) have been validated against a range of phar-
maceutical targets (including renin aspartic protease, elastase and
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glucocerebrosidase), showing excellent agreement with binding sites
identified by X-ray crystallography, for both organic solvents and
drug molecules (41,43,44). These encouraging correlations with
existing structural data suggest that the FTMAP method also has
the potential to work in a prescriptive fashion, in the identification
of novel druggable allosteric binding sites.
The aforementioned mapping algorithms typically depend on the
availability of one, or occasionally a few, experimentally determined
atomic structures of the target protein. Considering the structural
flexibility of proteins, this static representation of the target can be
extremely restrictive and is a recognized flaw in many protein–
ligand docking efforts (45,46). Consequently, a variety of schemes
have been proposed that allow target flexibility to be taken into
account and range from modeling simple sidechain changes to full
backbone and sidechain mobility (47,48). In the context of binding
site identification, the incorporation of protein flexibility is appeal-
ing as allosteric pockets may only form transiently and relatively
infrequently in the dynamics of the protein and may therefore be
missed in experimental structures. Also, the topography of allosteric
sites may change, exposing different protein residues and altering
their physicochemical properties. The role of flexibility is even more
pronounced in the case of GPCRs, renowned for their strong intrin-
sic conformational plasticity that has hampered crystallization
efforts (49). Molecular dynamics (MD) simulation is a popular
method for the modeling of protein motions and generation of
ensembles of protein conformations, which evolve from an experi-
mental starting structure (50). Several MD simulation approaches
have now been reported, examining the conformational dynamics of
GPCRs, often with a view to capturing the structural rearrange-
ments that accompany receptor activation [e.g. (51,52)]. MD simula-
tions have also demonstrated their value in drug discovery
applications by exposing dramatic binding site changes. For exam-
ple, a relatively short (2 ns) MD simulation of HIV-1 integrase
revealed a new inhibitor binding site that led to the discovery of
the first integrase inhibitor, raltegravir (53). More subtle binding site
dynamics have been used in virtual screening applications, whereby
putative compounds are docked to a range of conformers, as
opposed to a single, experimental structure, to improve rank order-
ing (54). It is therefore appealing to couple a computational map-
ping analysis with an MD-based ensemble of GPCR conformations,
so as to potentially discover novel allosteric sites, as well as fur-
ther characterizing any existing sites.
In this work, we report the computational mapping of potential allo-
steric sites on the surface of the human b1 (b1AR) and b2 (b2AR)
adrenergic receptors (Figure 1), which may be exploited in the struc-
ture-based design of allosteric ligands. The recent milestone of
high-resolution crystal structures for these pharmaceutically impor-
tant GPCRs makes them ideally suited to such a mapping analysis.
b1AR and b2AR are members of the b-adrenoceptor subfamily of
Class A GPCRs and play key roles in heart muscle contraction and
bronchial smooth muscle relaxation, respectively. They have there-
fore been targeted in the treatment of heart disease and pulmonary
problems, through a range of orthosteric drugs. Unfortunately, these
receptors typify a limitation endemic throughout GPCRs, and indeed
many other drug targets, in the extremely high sequence conserva-
tion of their OSs (94% identity over 16 residues). Consequently,
subtype selectivity is a key issue in their pharmacological control,
and there is a pressing need to identify drugs with a greater capac-
ity to discriminate between related receptors. Allosteric drugs pose
one such solution, and we have therefore employed the FTMAP
algorithm to search for druggable hot spots in non-orthosteric
regions of the receptors. To address the role of conformational flex-
ibility, we have applied FTMAP to both the experimental structure
and an ensemble of 15 representative MD simulation structures, for
each receptor. Here, we used the multicopy MD approach, whereby
a series of six independent 40-ns trajectories was generated for
each receptor in a phospholipid bilayer, yielding a combined total
simulation time of approximately 0.5 ls. This study was inspired by
previous work that used the CS-Map algorithm to expose novel
binding sites in MD snapshots of a soluble viral target – the H5N1
influenza neuraminidase (55). The current work is distinguished by
use of the improved FTMAP code and its application to a pair of
human membrane protein targets, as well as a global search of the
entire protein surface. Our results define a set of five key non-
orthosteric regions that act as consensus binding sites for organic
probes and which may represent targets for allosteric ligands. Inter-
estingly, the sites are distributed across both solvent-exposed and
lipid-exposed surfaces, and it appears that one site may be exclu-
sive to one receptor subtype, while all others are generally shared.
Furthermore, some of the sites are not apparent in the experimental
structures, only being revealed in the MD-generated conformers.
We characterize each site in the context of experimental data and
propose they will serve to guide fragment-driven and virtual screen-
ing studies for the identification of allosteric compounds, which
may be shared with related GPCRs.
Methods
Mapping algorithm
Each receptor conformation was mapped for potential small mole-
cule binding sites using the fragment-based FTMAP algorithm (41),
through its online server (http://ftmap.bu.edu). FTMAP scans the
global surface of the protein with a diverse library of 16 small
organic probe molecules, with varying hydrophobicity and hydrogen-
bonding capability (ethanol, isopropanol, isobutanol, acetone, acetal-
dehyde, dimethyl ether, cyclohexane, ethane, acetonitrile, urea,
methylamine, phenol, benzaldehyde, benzene, acetamide and N,N-
dimethylformamide). A fast Fourier transform correlation approach is
used for this step, sampling billions of receptor–probe complexes.
Each complex is evaluated using an energy expression that includes
terms for the van der Waals and electrostatic interaction energy, as
well as solvation effects. The 2000 most favorable docked positions
of each probe are then energy-minimized and clustered. For each
probe, the six clusters with the lowest mean interaction energy are
retained. Next, these low-energy clusters from different probe types
are themselves clustered into CSs, which define hot spots where
multiple probes congregate with high affinity. It has been shown
that such behavior is characteristic of a druggable site, which can
therefore be distinguished from unimportant isolated sites. The CSs
are ranked by the number of probe clusters they incorporate, with
the largest CSs proposed to represent the most important sites of
interest. In this work, the 10 largest CSs have been analyzed –
named CS1 (largest CS) through CS10 (smallest CS). Note that
Computational Mapping of Novel Druggable Sites on GPCRs
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multiple CSs may aggregate to form a single binding site, by repre-
senting the different moieties of a ligand. The main output from
the FTMAP server is a Protein Data Bank (PDB) file containing the
analyzed protein structure along with representative probe mole-
cules belonging to the clusters forming the CSs. By definition, these
hot spots typically contain a mixture of probe types, representing a
variety of sizes and non-bonded interactions with the protein. The
output also contains useful statistics on the specific protein resi-
dues that mediate non-bonded protein–probe interactions and
therefore contribute to the binding energy.
MD simulation setup
The 2.7  crystal structure of cyanopindolol-bound turkey b1AR
[PDB code 2VT4 (14)] was used as a template to model human
b1AR, with cyanopindolol removed from the OS. A pairwise
sequence alignment of the turkey and human sequences was gener-
ated using MUSCLE (56), yielding a high sequence identity of 81%.
The alignment was composed of two contiguous regions, separated
by the deleted ICL3: an N-terminal region containing TM1-TM5 and
a C-terminal region containing TM6-TM7. The MODELLER 9v4 pack-
age (57) was used to generate a set of homology models of human
b1AR from the alignment, with the lowest energy conformation
(based on the MODELLER energy term) selected for this study. An
initial conformation of the absent ICL3 was modelled between TM5
and TM6. A short energy minimization of the model structure was
carried out with the GROMACS package (58). The final b1AR struc-
ture represents residues 56 through 393.
The 2.4  crystal structure of carazolol-bound human b2AR [PDB
code 2RH1 (15)] was used for human b2AR, with carazolol removed
from the OS. The MODELLER 9v4 package was used to model an
initial conformation of the absent ICL3 between TM5 and TM6. A
short energy minimization of the model structure was carried out
with the GROMACS package (58). The final b2AR structure repre-
sents residues 29 through 342.
To accurately model the position of the receptors in a phospholipid
bilayer and allow relaxation of the modelled ICL3 in a membrane
environment, a coarse-grained (CG) simulation step was used. CG
simulations have been demonstrated as a rapid method for the
self-assembly of protein–lipid complexes and are therefore useful in
generating the initial co-ordinates for conventional MD simulations
of membrane proteins [see http://sbcb.bioch.ox.ac.uk/cgdb & (59)].
A
B
Figure 1: Snapshots of the bilayer-embedded b1AR (A) and b2AR (B) MD simulation systems. Receptors are shown in cartoon representa-
tion (left), with the seven TM helices colored blue and other structures colored orange. Residues comprising the orthosteric site (OS) are
shown in green stick representation. The co-crystallized orthosteric ligand is superimposed and shown in black molecular surface representa-
tion. Receptors are shown in molecular surface representation (center, right) to illustrate the regions being mapped by probes. Solvent-acces-
sible surfaces are colored green, while other regions are colored gray. Extracellular and intracellular views show the solvent-exposed regions
in more detail, from above and below the bilayer. Palmitoyl-oleoyl phosphatidylcholine phospholipid molecules are shown in space-filling rep-
resentation and are colored by atom type.
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For each receptor, the all-atom protein structure was first converted
into a reduced CG representation and surrounded with 256 ran-
domly positioned CG palmitoyl-oleoyl phosphatidylcholine (POPC)
molecules. This system was then solvated with approximately 5400
CG water particles and counterions. After energy minimization, an
800-ns (effective time) CG simulation was performed, whereby the
POPC lipids self-assembled into a bilayer phase around the inserted
receptor. All non-ICL3 residues were distance-restrained, such that
the core experimental structure was preserved, while the modelled
ICL3 loop was allowed to move in the solvent. As described in (60),
the 800-ns snapshot of the CG system was converted into atomistic
detail, by first superimposing the atomistic receptor model onto the
CG receptor model co-ordinates. The modelled ICL3 conformation
was then replaced with that captured in the final CG snapshot,
using the Pulchra algorithm (61). Next, the CG lipids were converted
into atomistic detail using a library of 1500 atomistic POPC lipids
taken from a simulation of a pure POPC bilayer. The atomistic lipid
with the lowest root-mean-square deviation (RMSD) to the CG lipid
backbone was used as a replacement. The 256-lipid reconstructed
bilayer was enlarged to 359 lipids to avoid periodicity artifacts in
the atomistic simulations, using molecules from periodic images.
Finally, the protein–bilayer complex was solvated with approxi-
mately 30 000 water molecules and counterions to preserve electro-
neutrality. The co-crystallized ligands in the orthosteric binding site
were thus replaced with water molecules.
The final simulation cell was of dimension 11 nm · 11 nm · 12 nm
and contained approximately 113 000 atoms. The bilayer-inserted
positions of both receptors and final conformations of ICL3 can be
seen in Figure 1. A final energy minimization of the entire system
was followed by a 3-ns equilibration phase, whereby all receptor
heavy atoms were position-restrained to allow a relaxation of the
packing of the lipids and solvent around the protein. Unrestrained
production runs were then simulated for 40 ns each. A total of
6 · 40 ns trajectories were generated for each receptor, which
were then concatenated into a single 240-ns trajectory for cluster-
ing. Such a multicopy technique has been shown to improve confor-
mational sampling in conventional MD simulations, when compared
to a single long simulation (62).
MD simulation details
All ionizable protein residues were assigned default protonation
states except for Glu-92 in b1AR and the equivalent Glu-94 in
b2AR, which were neutralized as they adopt lipid-exposed confor-
mations. The amino and carboxyl termini of the receptors were also
neutralized as they do not correspond to the actual receptor ter-
mini. The initial CG simulation step was performed using the MAR-
TINI forcefield (63) with the GROMACS v.3.3.1 MD simulation
package (58,64,65) and a 20 fs timestep. For the conventional MD
simulations, all energy minimization was performed using 100 steps
of the steepest descents algorithm. Equilibration was performed
using harmonic restraints on all protein heavy atoms (force con-
stant = 1000 kJ ⁄mol ⁄ nm2), a Berendsen thermostat (66) and a Ber-
endsen barostat to maintain pressure at 1 bar (66). Convergence of
the potential energy and volume of the system was used to ensure
adequate lipid and solvent relaxation during equilibration. A sepa-
rate equilibration (and subsequent production run) was performed
for each of the six copies of each system using a different randomi-
zation seed for the initial atomic velocities (62). The unrestrained
production runs were performed with a Nos–Hoover thermostat
(67,68), and pressure was maintained at 1 bar by a Parrinello–
Rahman barostat (69). Simulations were run in the NPT ensemble
and at a temperature of 310 K. Particle mesh Ewald was used to
treat long-range electrostatics (70), and the single point charge
water model (71) was used for the solvent (as recommended for
the GROMOS force field). Chloride anions were positioned randomly
among the solvent to neutralize the net positive charge of the
protein. An integration time step of 2 fs was used. The LINCS
algorithm was used to restrain all bond lengths (72). Simulations
were set up, performed and analyzed using the GROMACS v.3.3.1
MD simulation package (58,64,65). The GROMOS96 force field was
used (43A1 parameter set) (73), with lipid parameters based on
those described in (74). All molecular graphics were produced with
Visual Molecular Dynamics (VMD) (75).
Selecting representative MD structures
An ensemble of 15 MD structures, representative of each 240-ns
receptor trajectory, was generated using an RMSD-based conforma-
tional clustering algorithm. This approach has been shown to be an
effective way of capturing the conformational diversity of an MD
ensemble in a reduced dataset (76). For each 240-ns trajectory, sim-
ulation frames were saved every 50 ps, yielding a set of 4800 pro-
tein snapshots. All snapshots were superimposed using the Ca
atoms of nine key secondary structures to remove overall rotation
and translation: the seven TM helices, the 8th helix that lies on the
intracellular face of the membrane and the short helix contained
within ECL2 (representing 229 residues in b1AR and 227 residues in
b2AR). The RMSD-based clustering step was carried out on the
same set of Ca atoms, using the 'g_cluster' component of the GRO-
MACS package and a 1.5- cutoff. This large set of residues was
chosen as we are performing a global search of binding sites and
are therefore interested in receptor-wide structural changes. The
top 15 clusters of similar structures were retained, representing
96.8% of the b1AR trajectory and 99.4% of the b2AR trajectory.
The centroid structure from each cluster was used as the cluster
representative for mapping analysis (see Supporting Information for
distribution of cluster centroids).
Results and Discussion
MD simulation dynamics
Before discussing the mapping results, we briefly characterize the
structural variation captured in the MD simulations. To assess the
conformational drift of the structures, we measured the RMSD with
respect to the experimental starting co-ordinates (see Supporting
Information). Using the Ca atoms of the TM helices for an indica-
tion of global drift, the RMSD varies between 1.5 and 3 , typical
of many membrane protein simulations and indicative of structures
relaxing from their crystallization environment. The notable differ-
ence in the drift of the individual simulation copies is a hallmark
of the multicopy approach and is suggestive of the greater variation
in sampling compared to a single trajectory. It is also apparent
that the structures of some copies are still evolving from the
Computational Mapping of Novel Druggable Sites on GPCRs
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experimental structure, which may be attributed to the simulation
of the ligand-free state, the inherent structural plasticity of GPCRs
and timescale limitations. Figure 2 shows the superposition of
the MD ensemble and the experimental structure to illustrate the
substantial conformational changes that take place during the MD
simulations. As expected, the large, solvent-exposed ICL3 shows
the greatest movement, swinging toward and away from the TM
core of the protein, and in the case of b1AR occasionally plugging
the 'intracellular mouth' at the center of the TM helices. We
observe significant variations in the shape and size of this solvent-
exposed cavity, which has been shown to open to accommodate
portions of the G-protein in an opsin crystal structure (19). On the
extracellular surface, it has been predicted from experimental struc-
tures that ECL2 is constrained as it is tethered to the TM core
through a disulfide bridge to TM3, as well as containing an internal
disulfide bridge (21). While these bonds certainly restrict the confor-
mational freedom of ECL2, we observe motions that, in concert with
other extracellular features, modulate the accessibility of the OS by
opening and closing the 'extracellular mouth'. This gating function,
seen in both receptors, may have important implications for the
mechanism of allosteric modulation in this region and is discussed
in more detail later. In the TM region of the protein, we observe
inter-helical packing adjustments that may expose ligand-binding
opportunities in the hydrophobic environment of the bilayer core.
For example, TM1 exhibits strong fluctuations in its packing against
the TM bundle, often losing interactions with TM2 and moving
away from the core. Intra-helical changes are also apparent, for
example the well-known proline-induced kinking of TM6, which is
thought to be a conserved conformational switch in GPCR activation
and may be important in permitting GPCR:G–protein interactions. In
summary, a variety of structural rearrangements are embodied in
the MD ensemble, therefore presenting diverse topographies more
representative of GPCR dynamics than experimental structures
alone.
Mapping results
The results of the mapping of the experimental and MD structures
of both receptors are summarized in Figure 3, by depicting the glo-
bal distribution of the top 10 CSs identified. Before examining the
allosteric hot spots, it is useful to assess the identification of the
OS in the experimental structures, which were both solved in the
presence of orthosteric ligands. In each receptor, three neighbouring
CSs superimpose very well with fragments of the orthosteric ligand
(Figure 3, inset), with their constituent probe molecules tracing the
'L'-shaped geometry of the ligand and detecting ring moieties. For
b1AR, these CSs are ranked 1st, 4th and 6th, while for b2AR they
are ranked 2nd, 5th and 10th. This demonstrates that FTMAP is
capable of finding low-energy probe sites that correspond to experi-
mentally determined drug fragment sites and is consistent with
applications to other targets that also detect high overlap between
probes and drug molecules (41). The co-crystallized orthosteric drugs
are relatively large for known bAR ligands and likely cover the
majority of the OS. It is therefore reasonable to consider all other
hot spots as potential allosteric binding sites (referred to as 'non-
orthosteric'). For the experimental structures, the non-orthosteric
CSs are mainly found in subregions of the extracellular and intracel-
lular mouths, with smaller CSs located in two lipid-exposed regions.
The highest ranked non-OSs are both found on solvent-exposed
surfaces and the overall distribution of sites is very similar for both
receptors. The majority of CSs are contained within the bounds of
the bilayer thickness with the exception of a single CS exposed to
the intracellular bulk solvent in b1AR. Switching our focus to the
mapping of the MD ensemble, it is clear again that the extracellu-
lar mouth is the richest source of CSs in both receptors, spanning
both orthosteric and non-OSs and exploring new regions compared
to the experimental structures. The intracellular mouth is also an
important region for many probes, some of which penetrate more
deeply into the TM core than in the experimental structures, almost
to the center of the bilayer in the case of b1AR. Interestingly, novel
A B
Figure 2: Snapshots of the ensemble of 15 representative structures extracted from b1AR (A) and b2AR (B) MD simulations. The aligned
receptor structures are shown in cartoon representation, with the experimental conformation colored in blue and all 15 MD conformations col-
ored independently. Palmitoyl-oleoyl phosphatidylcholine (POPC) phospholipid molecules are shown in space-filling representation and are col-
ored by atom type. The structure of the POPC bilayer shown is taken from the beginning of the MD simulations.
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sites are found in the lipid-exposed surfaces of the MD structures,
which were not apparent in the experimental structures, forming
two CS clusters in the intracellular half of the bilayer and one CS
cluster in the extracellular half, as well as more isolated CSs. Con-
sidering the additional data available for the MD ensemble mapping
and the sampling of novel low-energy CSs that are conserved
across multiple conformers, we decided to focus our attention on
the MD-based probe dataset.
While a visual description of the CSs in the context of the experi-
mental structure is useful for a coarse analysis and illustrative pur-
poses, significant backbone and sidechain movements in the MD
structures can take place. To more precisely characterize the domi-
nant non-OSs of interest, we ranked the protein residues in each
receptor by the number of non-bonded interactions they make with
probe molecules belonging to the CSs (an interaction is counted
when a non-hydrogen probe atom is found within a 5  radius of a
non-hydrogen protein atom). The number of such interactions was
summed over all 15 MD structures and then listed as a percentage
of all protein–probe interactions for the MD ensemble. This statistic
therefore ranks the key binding site residues by their overall perfor-
mance in the ensemble, as opposed to isolated conformers. After
plotting the number of interactions per residue, it was decided to
focus on the top 40 probe-interacting residues of each receptor
(see Supporting Information). Figure 4 illustrates the distribution of
these residues in each receptor and assigns them as either ortho-
steric or non-orthosteric based on their proximity to the orthosteric
ligand in the experimental structures. As expected, a core of ortho-
steric residues leads the rankings and is then followed by a mixture
of orthosteric and non-orthosteric residues. The orthosteric residues
line a lower portion of the extracellular mouth, forming a deep
cleft. The non-orthosteric residues can be clustered into five distinct
groups, along with the probes they bind, as illustrated in Figure 4
and the members of which are listed in Table 1. Both receptors
have four non-orthosteric groups in common, with b2AR interest-
ingly containing a 5th group not seen in b1AR. Sites 1 and 4 are
found in the extracellular and intracellular mouths, respectively,
while sites 2, 3 and 5 are found at lipid-exposed surfaces. We now
explore each of the sites in more detail and in light of available
experiment data.
Site 1: extracellular mouth
Site 1 is found in the upper region of the extracellular mouth, in
the solvent-exposed cavity between the OS and the ends of each
TM helix (Figure 5). For b1AR, the probes tend to bind in the upper-
right region of the mouth, toward ECL1, while in b2AR probes
have a broader distribution and are also found directly above the
A
B
Figure 3: Mapping results for the b1AR (A) and b2AR (B) structures, showing the distribution of hot spots. The top 10 consensus sites
(CSs) are shown as spheres, depicting the center-of-mass of the hot spot and the radius of which denotes the ranking of the CS (see legend).
The mapping of the experimental structure is shown on the left, with the inset showing the probe molecules from the three CSs that overlap
with the co-crystallized ligand in the orthosteric site. The mapping of the MD ensemble is shown on the right, with all 15 sets of CSs dis-
played simultaneously and colored on a RGB color scale from red (MD cluster 1) through blue (MD cluster 15). Receptors are shown in blue
cartoon representation and depict the experimental conformation. The superimposed co-crystallized ligands are shown in transparent black
molecular surface representation (main) and blue stick representation (inset). Inset probe molecules are shown in ball-and-stick representation,
colored by atom type. Approximate limits of the bilayer are shown as white lines.
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orthosteric ligand, toward ECL3. On average, FTMAP identifies two
CSs in this region for each input MD structure, with a third of the
structures reporting the top ranked CS here. The key interacting
residues of this site stem from ECL2, TM2 and TM7 (and ECL1 in
b2AR) and cluster in a corner of the extracellular mouth. b2AR
contains an additional residue in ECL2 (Phe-194) that is largely
responsible for binding probes not seen in the same region in
b1AR. The locations of the residues are well shared between the
receptors, although it is clear that there is greater sequence diver-
sity here, compared to the OS, which makes it an appealing target
in terms of subtype selectivity.
The extracellular mouth of GPCRs is probably the most frequently
studied region in biochemical work investigating allosteric ligands,
so it was encouraging to see such a rich source of CSs found here.
Studies on muscarinic receptors have provided evidence for one or
more allosteric sites in the extracellular entrance, in a region above
and distinct from the deeper OS, consistent with Site 1 found here
(31,77). More specifically, residues from ECL2 and TM7, as seen in
Site 1, have been shown to interact with allosteric ligands. In ECL2,
acidic residues and a downstream tyrosine residue have been
proposed to bind allosteric compounds in muscarinic receptors [see
(26)], which may correspond to the aspartate residues found in both
bARs and the downstream phenylalanine residue found specifically
in b2AR. Various residues at the top of TM7 and beginning of
ECL3 have been implicated in allosteric binding roles in muscarinic
receptors [see (26)], including a lysine residue which is also seen in
A
B
Figure 4: Principal non-orthosteric interaction sites on b1AR (A) and b2AR (B). Top 40 residues interacting with probe molecules are
shown on the left, with orthosteric residues shown as green spheres and non-orthosteric residues shown as red spheres. Probes binding to
the non-orthosteric residues are shown in the center as green densities that have been clustered into five key regions, four of which are
shared between both receptors and one of which is exclusive to b2AR. A schematic depiction of the receptors and their key non-orthosteric
sites is shown on the right, with solvent-exposed regions shown as triangles and lipid-exposed regions shown as rectangles. Receptors are
shown in blue cartoon representation and depict the experimental conformation. The superimposed co-crystallized ligands are shown in black
molecular surface representation. Approximate limits of the bilayer are shown as white lines.
Table 1: Key probe-interacting residues forming the 4 non-or-
thosteric binding sites of b1AR and 5 non-orthosteric binding sites
of b2AR
GPCR Allosteric site Key interacting residues (secondary structure)
b1AR 1 Gly-115, Ile-118, Val-119 (TM2)
Cys-216, Asp-217 (ECL2)
Val-360 (TM7)
2 Trp-364 (TM7)
3 Glu-147 (TM3)
4 Thr-91, Leu-92, Thr-93, Asn-94, Ile-97 (TM2)
Arg-156 (TM3)
Tyr-166 (ICL2)
Pro-285, Pro-286 (ICL3)
Glu-319, Ala-322, Thr-325, Leu-326 (TM6)
b2AR 1 Gly-90, His-93, Ile-94 (TM2)
Asp-192, Phe-194 (ECL2)
Trp-99 (ECL1)
Lys-305, Ile-309 (TM7)
2 Trp-313 (TM7)
3 Glu-122, Cys-125 (TM3)
4 Thr-68, Asn-69 (TM2)
Arg-131 (TM3)
Ala-271 (TM6)
5 Thr-73, Ser-74, Cys-77, Ala-78, Val-81 (TM2)
Ile-154, Trp-158 (TM4)
Leu-115 (TM3)
GPCR, G-protein coupled receptor.
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the b2AR. While comparable experimental data for bARs is lacking,
these correlations suggest they may possess an analogous allosteric
site to the muscarinic receptors in this extracellular mouth region.
An important question is how compounds binding in the entrance
to the OS exert their allosteric effect. Muscarinic allosteric ligands
have been shown to act in a modulatory fashion, by inhibiting
either the dissociation or association of orthosteric ligands (i.e. pro-
hibiting their exit or entry to ⁄ from the extracellular medium) (78).
They have therefore been conceptualized as 'plugs', which seal the
entrance to the OS and either lock a bound orthosteric ligand in
place or prevent its ingress, with functional consequences. Experi-
mental work by Avlani and co-workers on the M2 muscarinic recep-
tor has demonstrated that despite the presence of stabilizing
disulfide bridges, ECL2 has the flexibility to modulate the accessibil-
ity of the OS, thus acting as a 'gatekeeper' (79). It was proposed
that the open state of the mouth would allow entrance of the
orthosteric ligand, followed by a closure that would increase the
number of receptor–ligand interactions. The results of our MD simu-
lations suggest that this gating feature is also shared by bARs as
the extracellular entrance is capable of motions that completely
seal off the water-filled OS. Using principal component analysis, we
observed that the dominant mode of global receptor motion in both
MD trajectories involved an opening ⁄ closing event at the extracellu-
lar end of the receptors that was not foreseen from the experimen-
tal structures alone. Figure 5 shows snapshots of the two receptors
that represent the most open and most closed states, in a move-
ment that is characterized by the movement of ECL2 toward and
away from the top of TM7. This movement is consistent with the
engineered closed state of the M2 muscarinic receptor, whereby a
disulfide bridge was introduced between sites corresponding to a
valine residue in ECL2 and an asparagine residue at the top of
TM7 (79). Avlani and co-workers proposed that allosteric ligands
binding in the vicinity of this gate region would therefore serve to
either (i) bind to and stabilize the closed form of the gate or (ii)
bind to the open form and therefore mimic the closed state of the
gate. Our results suggest that the former is more likely in the case
of bARs, as all probe-binding sites identified by FTMAP would be
concealed in the closed state and therefore inaccessible. A bound
allosteric ligand would therefore bridge the opposing components
of the gate and block the orthosteric ligand pathway. Further evi-
dence for this blocking model comes from our related work on the
binding of auto-antibodies to an antigenic site on ECL2 of the b1AR
in Chagas' disease (to be published elsewhere). Auto-antibody frag-
ments have been experimentally shown to block the accessibility of
the OS in b1AR (80), and our protein–protein docking results sug-
gest that antibody loops partially enter the extracellular mouth and
cover the entrance. In the case of b2AR, a recent NMR study has
supported the dynamic nature of the extracellular mouth, whereby
the formation of a salt bridge between Lys-305 of TM7 and Asp-
192 of ECL2 is shown to reflect the activation state of the receptor
(81). Interestingly, these residues are both identified in our study,
A
B
Figure 5: Non-orthosteric Site 1: the extracellular mouth region of b1AR (A) and b2AR (B). An extracellular view of the mouth region is
shown on the left, with bound probe molecules and key interacting residues. Bound probe molecules are shown in ball-and-stick representa-
tion and colored by atom type. Key residues are shown in space-filing representation and labeled. Receptors are shown in transparent blue
cartoon representation, with TM2 colored orange, TM7 colored white and ECL2 colored red. The experimental conformation of the receptor is
shown. The gating motion of the extracellular mouth region seen in the MD simulations is shown on the right, with snapshots of the open
and closed conformations. Receptors are shown in blue molecular surface representation, with TM2, TM7 and ECL2 colored orange, white
and red, respectively.
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and it was proposed that allosteric ligands binding in this vicinity
might also be able to influence the state of the receptor by them-
selves (i.e. independently of the orthosteric ligand). Finally, a third
potential class of allosteric ligand has been proposed in this region,
as it annexes the OS: so-called 'bitopic' or 'dualsteric' ligands
(78,82). Such ligands represent the fusion of an orthosteric and allo-
steric ligand, whereby the allosteric component confers subtype
specificity and the orthosteric component exerts functional effects.
Our results suggest that the rational design of such ligands is feasi-
ble in the case of bARs as there is sufficient spatial proximity
between the OS and the bound probe molecules for a small mole-
cule to span both locations. Indeed, there appears to be a degree
of overlap between the orthosteric and non-orthosteric probe mole-
cules, as has been noted for certain allosteric modulators (31). The
MD structures also demonstrate that the extracellular mouth has
the capacity to accommodate both elements of bitopic ligands
simultaneously, as probes are typically bound at both sites for the
same input structure.
Site 2: TM1-TM7 cavity
Site 2 is formed by a 'U'-shaped cavity that lies in between the
extracellular ends of TM1 and TM7, in the upper leaflet of the
bilayer (Figure 6). This space is segregated from the extracellular
mouth region by TM2 and thus lies at a protein–lipid interfacial
region. During both MD trajectories, this void is largely populated
by the fatty acyl chains of POPC phospholipid molecules, confirming
the hydrophobic environment of the pocket. This observation under-
scores the value of a short CG simulation to determine the initial
positioning of phospholipids, particularly in the annular shell coating
the receptor. FTMAP detects a single CS in this pocket in seven of
the b1AR MD structures and five of the b2AR MD structures. While
the CS is found in the experimental b1AR structure, it is not seen
in the experimental b2AR structure, only appearing through
MD-induced relaxations. This transient character contrasts with the
solvent-exposed Site 1 and suggests this pocket may form less fre-
quently and may be associated with particular states of the GPCR.
The key interacting residue of Site 2 is a tryptophan in TM7 that is
conserved in both receptors (Trp-364 in b1AR and Trp-313 in b2AR).
However, the peripheral sidechains lining the site show differences
that could be exploited in the design of subtype-selective ligands.
While experimental data supporting a role for allosteric ligand bind-
ing in this pocket is lacking, one might predict the conformational
consequences of small molecules 'wedging' this cavity open. For
example, TM7 contributes residues to the orthosteric binding site,
and therefore allosteric ligands may stabilize conformations that
favor orthosteric ligand binding or release. The intracellular end of
TM7 also contributes the 'NPXXY' motif, which is thought to be
involved in G-protein activation and might be constrained by a less
mobile TM7. Another possibility is that allosteric ligands at this site
may stabilize the open state of the extracellular mouth, as based
on the motions depicted in Figure 5, the movement of TM7 toward
ECL2 may be hindered. We note that the experimental structures
used in this study do not contain an N-terminal fragment of 55
(b1AR) and 28 (b2AR) residues that contained disordered and
deleted regions in the crystallization constructs. The fact that this
sequence annexes TM1 means we cannot exclude the possibility
that its omission affects the dynamics of this binding pocket.
Site 3: TM4–TM3–TM5 junction
Site 3 is formed by a cavity at the intersection of TM3, TM4
and TM5, in the lower leaflet of the bilayer (Figure 7). This site is
found on the exterior surface of the TM core and is therefore also
located at the protein–lipid interface. Similarly to Site 2, the pocket
is occupied by the fatty acyl chains of phospholipid molecules and
A B
Figure 6: Non-orthosteric Site 2: the TM1–TM7 cavity of b1AR (A) and b2AR (B). Side view of the cavity taken in the plane of the bilayer,
depicting bound probe molecules and the key interacting tryptophan residue. Bound probe molecules are shown in ball-and-stick representa-
tion and colored by atom type. Tryptophan residue is shown in brown space-filling representation and labeled. Receptors are shown in blue
molecular surface representation, with TM1 colored red and TM7 colored white. The experimental conformation of the receptor is shown.
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therefore represents another opportunity for potential hydrophobic
drugs to enter from the membrane. Single CSs are detected in 11
and 10 of the b1AR and b2AR MD structures, respectively, again
suggesting a transient nature whereby the chemistry and geometry
of the pocket change with protein dynamics. In the case of b2AR,
four of the structures also yield a second CS, suggesting the pocket
may be slightly larger for this receptor. Interestingly, this site is not
exposed by FTMAP in either of the experimental structures, further
supporting the role of incorporating target flexibility in the detection
of putative drug-binding sites. Conserved at Site 3 in both receptors
is a glutamate residue (Glu-147 in b1AR and Glu-122 in b2AR) that
interacts through backbone and methylene atoms, along with fur-
ther notable interactions from Cys-125 in b2AR (also conserved in
b1AR). As noted in Site 2, non-identical residues are found at other
locations in the pocket, which could support receptor selectivity.
Occurring at the junction between three of the seven TM helices, it
is likely that ligands binding in, and therefore occluding, this cavity
will have a strong influence on the conformational flexibility of the
receptor, potentially stabilizing certain activation states. In particu-
lar, TM3 contains residues upstream of the site that interact with
orthosteric ligands and a downstream residue engaged in the 'ionic
lock', proposed to be an important conformational switch in GPCR
activation. Thus, allosteric ligands at this site may have the capac-
ity to either modulate orthosteric ligand binding and ⁄ or influence
GPCR activation autonomously, by constraining key TM helices.
Interestingly, a recent experimental study of b1AR and b2AR
reported the substitution of bulky hydrophobic residues for Glu-147
and Glu-122 in Site 3 (83), with the aim of stabilizing GPCRs in
structural biology applications. The mutations were found to sub-
stantially increase the conformational stability of these GPCRs, and
it was proposed that this was induced by reducing the flexibility
of TM5, which contains a proline-induced break which lines the
binding pocket. The appearance of favorable probe-binding sites in
the vicinity of these glutamate residues in our work would therefore
appear to mimic such mutagenesis experiments and suggest
small molecules directed to this site may have important functional
consequences. Furthermore, it provides another potential role for
allosteric ligands in the facilitation of GPCR structural biology
experiments.
Site 4: intracellular mouth
Site 4 is found in the solvent-exposed cavity formed at the intracel-
lular entrance to the TM core (Figure 8). This pocket is smaller than
the extracellular opening, with its size and accessibility modulated
by movements of the TM helices and the large ICL3, respectively.
Outward movements of the TM helices in the MD simulations allow
probes to permeate deeper into the core, particularly so in the
vicinity of TM6. FTMAP detects CSs in this region for almost all
structures, typically with 1–3 clusters reported, suggesting it can
accommodate relatively large molecules. In both receptors, key
interacting residues are located on TM2, TM3 and TM6, with an
additional contribution from ICL2 and ICL3 in b1AR. The abundance
of probe-binding sites is perhaps not surprising given this is a
known protein–protein interaction site between GPCRs and their
cognate G-proteins. The recent crystal structure of bovine opsin
complexed with a synthetic peptide corresponding to a C-terminal
portion of a G-protein a subunit (GaCT) confirms this (19). The sur-
face of the superimposed GaCT fragment accommodates the major-
ity of the probes found in the mapping of this site, suggesting most
of them have overlapping binding sites with G-proteins (Figure 8).
However, the aforementioned deeper probes do appear to bind in
regions distinct from those occupied by the GaCT, along with a
cluster of probes in the vicinity of ICL2 in b1AR. It is therefore
unclear if potential compounds designed to interact with this site
would compete with native GPCR:G–protein interactions or bind in
addition to the G-protein. In the former case, competitive allosteric
ligands could obviously be used to attenuate GPCR signalling, by
A B
Figure 7: Non-orthosteric Site 3: the TM4-TM3-TM5 junction of b1AR (A) and b2AR (B). Side view of the cavity taken in the plane of the
bilayer, depicting bound probe molecules and the key interacting residues. Bound probe molecules are shown in ball-and-stick representation
and colored by atom type. Key residues are shown in green space-filling representation and labeled. Receptors are shown in blue molecular
surface representation, with TM4 colored red, TM3 colored orange and TM5 colored white. The experimental conformation of the receptor is
shown.
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blocking the G-protein interaction site. In the latter case, as it is
known that the opening of the intracellular mouth is required to
bind the G-protein in the case of opsin, one could imagine an allo-
steric modulator that binds deep in the pocket and stabilizes this
open ⁄ active state to enhance signalling. Interestingly, zinc ions
have been shown to have an allosteric impact on b2AR, with muta-
genesis experiments pinpointing their interaction site to a cluster of
residues at the base of TM5 and TM6, at the intracellular mouth
(84). It has been shown that zinc binding at this site facilitates the
binding of the distant orthosteric ligand, and it has been proposed
that the ions bridge TM5 and TM6 and stabilize an activated state
of the GPCR. While this site does not appear in our mapping of the
intracellular mouth, we note that key interactions are instead made
between probe molecules and elements of another key conforma-
tional switch – the ionic lock (Arg-156 and Glu-319 in b1AR and
Arg-131 in b2AR). The separation of this salt bridge is thought to
be a hallmark of activated GPCR states and thus small molecules
binding in between them may stabilize these states, preventing ref-
ormation of the lock.
Site 5: cholesterol-binding site
Site 5 is found at the intersection of TM2, TM3 and TM4, in the
lower leaflet of the lipid bilayer (Figure 9). This site represents the
third lipid-exposed groove discovered and is also lined with the
fatty acyl tail of POPC lipids in the MD simulations. Site 5 is unique
in that it is the only binding pocket identified exclusively in one of
the receptor types – b2AR. For this structure, between 1 and 3 CSs
are detected in 10 of the 15 MD structures, with the two most
populated MD representative structures yielding the largest CS in
this area. Consequently, 8 of the top 40 probe-binding residues
from the b2AR analysis stem from the neighbouring TMs. In
contrast, single CSs are identified in only two of the 15 b1AR
MD structures, with no residues identified in the top 40. For both
experimental structures, no probe molecules were found at this site,
requiring MD simulation to become exposed. The clear difference in
the predicted probe-binding capacity of this region poses important
possibilities for subtype-selective drugs, if ligand interactions at this
site have functional consequences. Cholesterol has been known to
modulate the function of several GPCRs (85), and a new b2AR crys-
tal structure has recently clarified the significance of co-crystallized
cholesterol molecules that are seen to bind in the lower half of the
receptor (86). It was shown that there is a pair of cholesterol mole-
cules that binds specifically to a single site between TMs 1–4 and
does not appear to be a crystal packing artifact. Furthermore, it
was reported that a cholesterol analog increased the conforma-
tional stability of the receptor and that cholesterol can modulate
the orthosteric ligand-binding properties, suggestive of an allosteric
effect. Figure 9B shows the superposition of the pair of co-crystal-
lized cholesterol molecules with Site 5 of b2AR and the bound
probe molecules from our study. The majority of the probes overlap
well with cholesterol site 1 (which produces more protein interac-
tions than site 2), suggesting small molecules directed to this site
may be able to mimic the allosteric effects of cholesterol. Such
compounds would effectively fill the void between the three TM
helices, in a manner similar to that shown for Site 3 in Figure 7,
constraining the conformational flexibility of the receptor and poten-
tially stabilizing certain conformers. Indeed, Hanson and co-workers
(86) have proposed that the cholesterol-binding site represents a
potential therapeutic target. Interestingly, it has been shown that
the lipophilic bAR agonist salmeterol interacts with b2AR at both
the OS and an 'exosite' involving residues 149–158 of TM4 (87).
It is thought that this lipid-exposed secondary site, which overlaps
with residues identified in our study, allows the drug to become
'anchored' to the receptor and is responsible for its desirable
prolonged action. Site 5 may therefore form part of the salmeterol
exosite, providing an interaction site for the lipophilic tail of the
drug. Importantly, this allosteric site is not found in b1AR, sup-
porting our observations and demonstrating this site can confer
subtype specificity. Concerning the disparity between the predicted
A B
Figure 8: Non-orthosteric Site 4: the intracellular mouth region of b1AR (A) and b2AR (B). A view of the mouth region taken in the plane
of the bilayer, depicting bound probe molecules and the key interacting residues. Bound probe molecules are shown in ball-and-stick represen-
tation and colored by atom type. Key residues are shown in stick representation and labeled. Key TM helices are shown in cartoon represen-
tation, with TM2 colored orange, TM3 colored red, TM6 colored gray and ICL2 colored purple. The experimental conformation of the receptor
is shown, with other structures obscured for clarity. The superimposed GaCT fragment is shown in transparent black molecular surface repre-
sentation.
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druggability of this site in both receptors, we have compared
the amino acids lining the region to identify the chemical basis.
Based on the residues interacting with probes in b2AR, the three
substitutions are Cys-77->Ser-102 and Thr-73->Met-98 in TM2 and
Ile-154->Val-179 in TM4 (b2AR->b1AR). Based on the strict choles-
terol consensus motif (strict-CCM) proposed as a cholesterol-binding
signature (86), the important substitution is Tyr-70->Leu-95
(b2AR->b1AR), which is not a strong probe-binding site in our work.
We speculate that the lack of probe binding at this site in b1AR
might reflect a similar absence of cholesterol binding and that the
CCM may need to be expanded to embrace other residues, particu-
larly in TM2.
Conclusions
The allosteric modulation of GPCR activity is the focus of a growing
branch of drug discovery, searching for novel therapeutic agents to
control the numerous pathologies they play a role in. Among a
range of advantages over their orthosteric counterparts, allosteric
ligands offer the prospect of highly specific targeting, by binding to
less conserved regions of the receptor surface. Despite the devel-
opment of experimental screening methods for allosteric GPCR lead
discovery, in silico structure-based approaches are lacking, largely
because of the renowned problems associated with GPCR crys-
tallization. In the absence of experimental structures of GPCRs
complexed with allosteric ligands, there is a clear window of oppor-
tunity for predictive computational approaches using recent unbound
structures. In this work, we report the application of a fragment-
based algorithm, FTMAP, to map the surface of the human b1AR
and b2AR GPCR structures for druggable sites distinct from the OS.
To incorporate the flexibility of the receptors, we have mapped a
series of 15 diverse structures taken from a series of MD simula-
tions of each receptor in a phospholipid bilayer.
By focusing on the key interacting protein residues, we have
defined a set of five putative allosteric binding sites, four of which
are shared between receptor types and one of which is unique to
b2AR, which we have interpreted with corroborating experimental
evidence. Sites 1 and 4 are found in the solvent-exposed extracel-
lular and intracellular mouths, with Site 1 representing a well-
known region of allosteric ligand-binding activity in related GPCRs.
Key gating motions from MD simulations suggest that allosteric
ligands binding at the extracellular mouth may block the entrance
or exit of orthosteric ligands by bridging opposing structures at the
entrance. The possible function of allosteric ligands at Site 4 is
less clear, as this is an interaction site for G-proteins; however, we
speculate they may be capable of stabilizing the open form of the
cavity and influencing the conformation of the ionic lock. Sites 2, 3
and 5 represent pockets formed at the protein–lipid interface, in
the hydrophobic core of the lipid bilayer. Occupying the junctions of
TM helices, it is likely that compounds filling these locations would
increase inter-helical packing interactions and thus restrict confor-
mational flexibility. This effect is supported by experimental evi-
dence at Sites 3 and 5, where occlusion of the pockets has been
shown to increase stability of the receptors and may stabilize dis-
tinct states with desirable therapeutic effects. Site 5 is of particu-
lar interest as significant probe-binding events are only seen in
b2AR, suggesting it may be an excellent target for b2AR-selective
therapies. While structural evidence of protein–drug interactions in
the hydrophobic core of the membrane is lacking, a number of lipo-
philic drugs have demonstrated strong membrane partitioning coef-
ficients and have been proposed to access their membrane-
associated receptors from the lipid phase rather than the aqueous
phase (88).
From a methodological point of view, the use of MD simulations to
model flexibility of the receptors allowed FTMAP to detect some
sites not apparent in the static experimental structures and for us
A B
Figure 9: Non-orthosteric Site 5: the cholesterol-binding site of b2AR. A view of the cholesterol-binding region taken in the plane of the
bilayer, depicting bound probe molecules and the key interacting residues. Bound probe molecules are shown in ball-and-stick representation
and colored by atom type. Key residues are shown in stick representation and labeled. Key TM helices are shown in cartoon representation
(A), with TM2 colored orange, TM3 colored red and TM4 colored white. b2AR is also shown in blue molecular surface representation (B),
along with the two superimposed cholesterol structures, shown in pink stick representation, to show overlap between probe molecules and
cholesterol 1. The experimental conformation of b2AR is shown.
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to observe the transient nature of some pockets. Sampling different
receptor conformations is especially appealing for such flexible pro-
teins as GPCRs, as even subtle rearrangements may expose or con-
ceal key 'cryptic' binding sites. Given the broad distribution of the
representative MD structures used in this study (see Supporting
Information), we conclude that a multi-copy simulation approach of
this timescale is successful in generating enhanced conformational
diversity. However, despite recent advances in the evolution of com-
puter hardware, conventional MD simulations still suffer from
incomplete conformation sampling for systems of this size. It seems
reasonable to predict that a more extensive exploration of the con-
formational landscape could lead to the identification of further
druggable binding sites. It is therefore tempting to apply new com-
putational methods in the generation of more diverse structural
ensembles. Such methods include accelerated MD (89), replica
exchange (90) and conformational flooding (91) and may expose
sites that are formed in regions of the energy landscape distant
from the experimentally captured conformation.
Having identified a series of potential allosteric binding sites, this
work will serve as a springboard for structure and fragment-based
lead identification methods. An obvious starting point is in the vir-
tual screening of existing drug-like compound libraries for potential
high-affinity ligands at each pocket, which can then be assayed for
binding and allosteric activity. An alternative approach involves the
design and synthesis of novel compounds using the poses of
docked probe molecules from our analysis with fragment-based
techniques (92). Probes can be grown into high-affinity small mole-
cules that interact with further protein residues (fragment evolu-
tion). Also, when multiple probes are bound simultaneously, they
can be fused to form a single molecule (fragment linking). This
approach could also be used to form proposed bitopic compounds
in the extracellular mouth of the receptors, by joining orthosteric
compounds to putative allosteric probes (82). While the GPCRs fea-
tured in this study are logical targets to begin such screening stud-
ies and are of considerable therapeutic interest in their own right,
it is likely that additional druggable sites are present on related
GPCRs, which may be amenable to homology modeling approaches
for a similar analysis.
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